Editor: What To Know
- , a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it will release results from its prospective, multi-center, pivotal clinical trial (NCT03112005) on the EyeArt® AI Eye Screening System for autonomous detection of diabetic retinopathy (DR) at the Association for Research in Vision and Ophthalmology (ARVO) Imaging in the Eye Conference this weekend in Vancouver, British Columbia.
- Schenk Chair in Ophthalmology and Director of Retina Service at the University of Illinois at Chicago, will present results from the EyeArt prospective, pivotal clinical trial “Artificial Intelligence Screening for Diabetic Retinopathy.
- ” The presentation will be part of the 2019 ARVO Imaging in the Eye Conference at 5.
Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that it will release results from its prospective, multi-center, pivotal clinical trial (NCT03112005) on the EyeArt® AI Eye Screening System for autonomous detection of diabetic retinopathy (DR) at the Association for Research in Vision and Ophthalmology (ARVO) Imaging in the Eye Conference this weekend in Vancouver, British Columbia.
- On behalf of the 15-center study team, Jennifer Lim, MD, Marion H. Schenk Chair in Ophthalmology and Director of Retina Service at the University of Illinois at Chicago, will present results from the EyeArt prospective, pivotal clinical trial “Artificial Intelligence Screening for Diabetic Retinopathy: Analysis From a Pivotal Multi-Center Prospective Clinical Trial.” The presentation will be part of the 2019 ARVO Imaging in the Eye Conference at 5:15 p.m. PDT on Saturday, April 27, 2019, in the Vancouver Convention Centre (East) Ballroom A and B.
- In addition, the clinical team from the Washington University School of Medicine (St. Louis) will present results from its independent clinical study involving the EyeArt® AI Eye Screening System in real-world clinical applications:
- “Cost-Effectiveness of Primary Care-Based Non-Mydriatic Fundus Photography with Automated Retinal Image Analysis Screening Among Low-Income Patients with Diabetes,” which will be presented at 11 a.m. PDT on Wednesday, May 1, 2019, in the Vancouver Convention Centre (West) Room 220.
- “Diabetic Retinopathy Screening in a Primary Care Setting Using Non-Mydriatic Photography and Automated Retinal Image Analysis Improves Compliance with Follow-Up Ophthalmic Care,” which will be Poster B0005 at 3 p.m. PDT on Wednesday, May 1, 2019, in the Vancouver Convention Centre West Exhibition Hall.
Eyenuk Inc. will showcase its EyeArt® AI Eye Screening System for autonomous detection of DR at Booth #1637 at the Vancouver Convention Centre Exhibition Hall. In addition, key management team members will be available to meet with researchers, clinicians and potential industry partners during the ARVO annual meeting..
